Furthermore, the ExteNET trial confirmed that extending the adjuvant regimen with the tyrosine kinase inhibitor (TKI) neratinib for one year increased the clinical benefit of anti-HER2 adjuvant therapy, particularly in HR-positive/HER2-positive breast cancer patients [31]. This evidence concerns the gene ERBB2 and breast cancer.